Just a few years since pioneering a Covid-19 vaccine, Moderna faces a hostile political environment and a looming patent ...

The United States led the world in developing the technology that beat the COVID-19 pandemic. Action from lawmakers may leave ...

Before joining Moderna, Cronin spent close to 20 years at Ogilvy, working within its global healthcare department in ...

What’s Up With mRNA Research? A research nurse holds an injection of a BioNTech mRNA cancer immunotherapy for non-small cell ...

Vaccine makers Moderna Inc (NASDAQ:MRNA) and Novavax Inc (NASDAQ:NVAX) are facing selling pressure on Wednesday following reports suggesting the Trump administration will end support for Gavi.

Cronin has worked at Moderna since 2021, when she was brought on to market the biotech company’s COVID-19 vaccine.

Scientists say that officials from the National Institutes of Health urged them to remove references to mRNA vaccine ...

Is it time to average down on a Moderna holding or begin a new position? Let's look at the company's recent performance and ...

Just a few years since pioneering a Covid-19 vaccine, Moderna faces a hostile political environment and a looming patent problem. We recently compiled a list of the 12 Most Promising Biotech ...

The Trump administration’s decision to cut funding for Gavi, as part of a broader reduction in foreign aid, may have significant implications for vaccine makers. The move is expected to scale back ...

Shares of vaccine-maker Moderna MRNA closed at $34.71 on Monday, close to their 52-week low of $29.25. Moderna is facing several headwinds, including the declining COVID-19 vaccine and the soft ...